ClinicalTrials.gg
CompletedNCT05793684VicTorUpdated Nov 15, 2023

AD816 Crossover Study

A Phase 2 interventional study of Period A and Period B in OSA and Obstructive Sleep Apnea, sponsored by Apnimed. Completed at 3 sites in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2023-11-15.

Sponsored by Apnimed · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was Nov 2023, 3 years ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
25
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 13 studies in Sleep Apnea, Obstructive by Apnimed — 1 open to participants now, 1 under way, 1 of them phase 3. Sleep Apnea, Obstructive · Apnimed.

Enrollment
10th of 13
25 · median 60
Started
2023
with 2 others
Phase 2
9 of 13
none open now
Registered
9th of 13
by date

Among the 13 studies in Sleep Apnea, Obstructive by Apnimed, this one is the 10th largest by enrollment, is one of 3 that started in 2023, is one of 9 in phase 2, and was the 9th registered.

Sleep Apnea, Obstructive

2,246 studies on the registry are indexed under Sleep Apnea, Obstructive; 476 are open to participants now.

Browse Sleep Apnea, Obstructive studies →

Open to participants now

1 of the 13 studies in Sleep Apnea, Obstructive by Apnimed is open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

Where they have run

Who these studies take

Of the 317 Sleep Apnea, Obstructive studies recruiting now, 149 (47%) set no upper age limit and 124 (39%) stop at 75 or younger; 53 take children under 18; 66 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies in Sleep Apnea, Obstructive by Apnimed, or all of them as a file.
02

Study summary

The VicTor Study is a randomized, double blind, placebo-controlled, 3-period, multiple-dose crossover study in participants with OSA.

03

Conditions studied

  • OSA
  • Obstructive Sleep Apnea
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Between 18 to 75 years of age, inclusive, at the Screening Visit
  2. PSG criteria (V2 only)

    1. AHI4 (Hypopneas defined by 4% oxygen desaturation) of 10-45, inclusive
    2. ≤25% of events are central or mixed apneas
  3. PROMIS Fatigue or sleep related impairment or sleep disturbance (raw score): >11, i.e. at least "very mild symptoms" at V1
  4. between 18.5 and 40 kg/m2, inclusive

    Male participants:

  5. If sexually active with female partner(s) of , participant must agree, from Study Day 1 through 1 week after the last dose of study drug, to practice the protocol specified

    Female participants:

  6. If of childbearing potential (WOCBP), the participant must agree, from Study Day 1 through 1 week after the last dose of study drug, to practice the protocol specified contraception. All WOCBP must have negative result of a serum pregnancy test performed at screening.

    a. Females of non-childbearing potential include (defined as age ≥ 55 years with no menses for 12 or more months without an alternative medical cause) or permanently sterile (e.g. bilateral oophorectomy, bilateral salpingectomy or hysterectomy).

  7. Participant voluntarily agrees to participate in this study and signs an Institutional Review Board (IRB)-approved prior to performing any of the Screening Visit procedures.
  8. Participant must be able to understand the nature of the study and must have the opportunity to have any questions answered

Exclusion criteria

Exclusion Criteria:

  1. Current sleep disorder other than OSA of a severity that would interfere with study participation or interpretability of data.
  2. Clinically significant craniofacial malformation or grade ≥3 tonsillar hypertrophy.
  3. Current clinically significant cardiac disease (e.g., rhythm disturbances, coronary artery disease or cardiac failure) or poorly controlled hypertension (>140/90mmHg).
  4. Long syndrome or family history of long QT syndrome
  5. Current clinically significant neurological disorder, including epilepsy/convulsions.
  6. Other active major organ system disease including renal failure, lung disease, neuromuscular disease, or liver disease.
  7. Schizophrenia, schizoaffective disorder or bipolar disorder according to -5 (DSM-5) or International Classification of Disease tenth edition criteria.
  8. Attempted suicide within 1 year prior to screening, or current suicidal ideation.
  9. Clinically significant urinary retention, gastric retention or other severe decreased gastrointestinal motility condition.
  10. Benign prostatic hypertrophy that is actively being treated with alpha-1 adrenergic antagonist
  11. Severe or frequent gastroesophageal reflux or constipation
  12. Medically unexplained positive screen for drugs of abuse (excluding THC/marijuana) or history of substance use disorder as defined in DSM-V within 24 months prior to Screening Visit.
  13. A serious illness or infection in the past 30 days as determined by investigator.
  14. Clinically significant cognitive dysfunction as determined by investigator.
  15. Untreated narrow angle glaucoma.
  16. Women who are pregnant or nursing.
  17. CPAP should not be used for at least 2 weeks prior to first study PSG and during entire participation in the study.
  18. History of using oral or nasal devices for the treatment of OSA may enroll as long as the devices are not used for at least 2 weeks prior to first study PSG and during participation in the study.
  19. History of using devices to affect participant sleeping position for the treatment of OSA, e.g. to discourage supine sleeping position, may enroll as long as the devices are not used for at least 2 weeks prior to first study PSG and during participation in the study.
  20. Chronic oxygen therapy.
  21. Patients with hypoglossal nerve stimulation implant. Prior/Concurrent Clinical Study Experience
  22. Use of another agent within 30 days or 5 half-lives, whichever is longer, prior to dosing.
  23. Prolonged QT interval (> 450 ms in men or > 470 ms in women, after correction with most appropriate formula for observed heart rate), hypokalemia or hypomagnesemia (defined as >0.1 mEq/L below lower limit of normal for the testing laboratory).
  24. Hepatic transaminases >2X the (ULN), total >1.5X ULN (unless confirmed Gilbert syndrome), estimated \< 50 ml/min.
  25. Night- or shift-work sleep schedule which causes the major sleep period to be during the day, or planned travel across more than 1 time zone during the anticipated enrollment period
  26. Employment as a commercial driver or operator of hazardous equipment.
  27. Typically smoking more than 10 cigarettes or 2 cigars per day (or equivalent Vaping), or inability to abstain from smoking during overnight PSG visits.
  28. Unwilling to use specified .
  29. History of regular alcohol consumption of more than 14 standard units per week (males) or more than 7 standard units per week (females), or unwillingness to limit alcohol consumption to no greater than 2 units/day (males), 1 unit per day (females). Alcohol is not to be consumed within 3 hours of bedtime or on PSG nights.
  30. Unwilling to agree to limit during the study period caffeinated beverage intake (e.g., coffee, cola, tea) to 200 mg/day or less of caffeine, not to be used within 3 hours of bedtime. Viloxazine may increase the duration of effect of caffeine.
  31. Any condition that in the investigator's opinion would present an unreasonable risk to the participant, or which would interfere with their participation in the study or confound study interpretation.
  32. Participant considered by the investigator, for any reason, an unsuitable candidate to receive viloxazine or AD816 components, or unable or unlikely to understand or comply with the dosing schedule or study evaluations.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Participant, Investigator)
Enrollment
25 participants (actual)

Study arms

  • Experimental
    Order: Period A, Period B, Period C

    The sequence of periods for each participant are assigned in random order. Each of the three crossover periods is 14 days of uninterrupted nightly dosing, with an initial lower-dose week of investigational product (IP) followed by a higher dose week (or placebo each week).

    Drug: Period A · Drug: Period B · Drug: Period C

  • Experimental
    Order: Period B, Period C, Period A

    The sequence of periods for each participant are assigned in random order. Each of the three crossover periods is 14 days of uninterrupted nightly dosing, with an initial lower-dose week of investigational product (IP) followed by a higher dose week (or placebo each week).

    Drug: Period A · Drug: Period B · Drug: Period C

  • Experimental
    Order: Period C, Period A, Period B

    The sequence of periods for each participant are assigned in random order. Each of the three crossover periods is 14 days of uninterrupted nightly dosing, with an initial lower-dose week of investigational product (IP) followed by a higher dose week (or placebo each week).

    Drug: Period A · Drug: Period B · Drug: Period C

  • Experimental
    Order: Period A, Period C, Period B

    The sequence of periods for each participant are assigned in random order. Each of the three crossover periods is 14 days of uninterrupted nightly dosing, with an initial lower-dose week of investigational product (IP) followed by a higher dose week (or placebo each week).

    Drug: Period A · Drug: Period B · Drug: Period C

  • Experimental
    Order: Period B, Period A, Period C

    The sequence of periods for each participant are assigned in random order. Each of the three crossover periods is 14 days of uninterrupted nightly dosing, with an initial lower-dose week of investigational product (IP) followed by a higher dose week (or placebo each week).

    Drug: Period A · Drug: Period B · Drug: Period C

  • Experimental
    Order: Period C, Period B, Period A

    The sequence of periods for each participant are assigned in random order. Each of the three crossover periods is 14 days of uninterrupted nightly dosing, with an initial lower-dose week of investigational product (IP) followed by a higher dose week (or placebo each week).

    Drug: Period A · Drug: Period B · Drug: Period C

Interventions

  • DrugPeriod A

    Week 1: Viloxazine low dose + placebo; Week 2: Viloxazine high dose + placebo

  • DrugPeriod B

    Week 1: AD816 low dose; Week 2: AD816 high dose

  • DrugPeriod C

    Week 1: Placebo + Placebo; Week 2: Placebo + Placebo

06

What researchers measure

Primary outcomes

  1. Apnea-hypopnea index (AHI) 4%, AD816 vs. Placebo

    Apnea-hypopnea index based on 4% hypopnea desaturation

    Time frame: 14 days of treatment dosing per crossover arm (collected at the end of treatment dosing per crossover arm)

07

Study locations

3 sites
  • Santa Monica Clinical Trials
    Los Angeles, California 90025, United States
  • Brigham and Women's Hospital
    Boston, Massachusetts 02115, United States
  • Clayton Sleep Institute
    Saint Louis, Missouri 63143, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2023 to primary completion in Nov 2023, 6 months.

Of 47 phase 2 interventional studies under Sleep Apnea, Obstructive, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 46. This study's 6 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 18, 2023
First posted
Mar 31, 2023
StartActual
Apr 28, 2023
Primary completionActual
Nov 9, 2023
CompletionActual
Nov 9, 2023
Last update
Nov 15, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 15, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05793684
Lead sponsor
Apnimed
Responsible party
Sponsor
First posted
Mar 31, 2023
Start date
Apr 28, 2023
Primary completion
Nov 9, 2023
Completion
Nov 9, 2023
Last update
Nov 15, 2023

Study contacts

Ronald Farkas, MD
study director · Apnimed Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion